• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CeriBell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    12/12/25 1:13:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email
    8-K
    false000186110700018611072025-12-112025-12-11

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 11, 2025

     

     

    CeriBell, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-42364

    47-1785452

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    360 N. Pastoria Avenue

     

    Sunnyvale, California

     

    94085

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 800 436-0826

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, $0.001 par value per share

     

    CBLL

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01

    Entry into a Material Definitive Agreement.

     

    On December 11, 2025, Ceribell, Inc. (the “Company”) and George Yagmourian and Josefa Yagmourian, Trustees of the Yagmourian 1984 Living Trust (the “625 Lessor”), entered into the Second Amendment, effective December 4, 2025 (the “625 Amendment”), to the Standard Industrial/Commercial Multi-Tenant Lease dated May 17, 2024 (the “Original 625 Lease,” and as amended, the “625 Lease”). The 625 Lease covers approximately 11,607 square feet of office space located at 625 N. Pastoria Ave., Sunnyvale, CA 94085. Pursuant to the 625 Amendment, the Company and the 625 Lessor agreed to extend the term of the 625 Lease through January 31, 2028, with a monthly rent of $34,821.00.

     

    On December 11, 2025, the Company and WTA Pastoria II LLC (the “360 Lessor”) entered into the First Amendment, effective December 8, 2025 (the “360 Amendment”), to the Lease dated July 13, 2021 (the “Original 360 Lease,” and as amended, the “360 Lease”). The 360 Lease covers approximately 15,600 square feet of office space located at 360 N. Pastoria Ave., Sunnyvale, CA 94085. Pursuant to the 360 Amendment, the Company and the 360 Lessor agreed to extend the term of the 360 Lease through January 31, 2028, with a monthly rent of $74,147.00.

     

    The foregoing descriptions of the 625 Amendment and the 360 Amendment do not purport to be complete and are qualified in their entirety by reference to the full texts of the 625 Amendment and the 360 Amendment, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

     

     

    Item 9.01

    Financial Statements and Exhibits.

     

    Exhibit No.

    Description

    10.1

    Second Amendment to Standard Industrial/Commercial Multi-Tenant Lease, effective December 4, 2025, by and between CeriBell, Inc. and George Yagmourian and Josefa Yagmourian, Trustees of the Yagmourian 1984 Living Trust.

    10.2

     

    First Amendment to Lease, effective December 8, 2025, by and between CeriBell, Inc. and WTA Pastoria II LLC.

    104

    Cover Page Interactive Data File, formatted in Inline XBRL.

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    CERIBELL, INC.

     

     

     

     

    Date:

    December 12, 2025

    By:

    /s/ Scott Blumberg

     

     

     

    Scott Blumberg
    Chief Financial Officer

     


    Get the next $CBLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    10/21/2025$19.00Strong Buy
    Raymond James
    6/24/2025$30.00Buy
    BTIG Research
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    SEC Filings

    View All

    CeriBell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Ceribell, Inc. (0001861107) (Filer)

    12/12/25 1:13:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CeriBell Inc.

    SCHEDULE 13G/A - Ceribell, Inc. (0001861107) (Subject)

    12/11/25 3:12:13 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by CeriBell Inc.

    144 - Ceribell, Inc. (0001861107) (Subject)

    12/9/25 4:05:29 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on CeriBell with a new price target

    Raymond James initiated coverage of CeriBell with a rating of Strong Buy and set a new price target of $19.00

    10/21/25 7:19:41 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on CeriBell with a new price target

    BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

    6/24/25 8:00:31 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on CeriBell with a new price target

    Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

    4/4/25 8:27:23 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management

    12/12/25 9:49:00 AM ET
    $ABT
    $CBLL
    $HTFL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Global AI Infrastructure Shift Ignites Biotech Growth Phase

    Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini 3[1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the shift[2] toward strict rules for AI in medical devices, signaling that the technology is finally ready for real-world commercial use. This rapid move from the lab to the mass market creates a massive opportunity for specialized operators including Aleen Inc. (CSE:ALEN), Moderna, Inc. (NASDAQ:MRNA), GE HealthCare (NASDAQ:GEHC), CeriBell, Inc. (NASDAQ:CBLL), and Palantir Te

    12/9/25 9:25:00 AM ET
    $CBLL
    $GEHC
    $MRNA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical Electronics
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution

    SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium screening and monitoring device. This clearance further establishes the Ceribell System as an AI-powered brain monitoring platform technology, extending the benefits to a larger population of critically ill patients and providing additional information to assist in diagnosing patients

    12/9/25 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burke William W exercised 32,728 shares at a strike of $3.97 and sold $720,671 worth of shares (32,728 units at $22.02) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    12/11/25 4:48:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Parvizi Josef sold $506,500 worth of shares (25,000 units at $20.26) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    12/10/25 8:00:03 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Robertson Rebecca B exercised 5,000 shares at a strike of $2.24 and sold $100,000 worth of shares (5,000 units at $20.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    12/10/25 1:02:57 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/17/24 4:14:38 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/16/24 4:18:06 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    View All

    Medtech Leader Erica Rogers Joins Ceribell Board of Directors

    SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell's Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently

    9/22/25 8:00:03 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

    —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

    11/19/24 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CeriBell Inc.

    SC 13G - Ceribell, Inc. (0001861107) (Subject)

    11/7/24 9:24:55 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by CeriBell Inc.

    SC 13D - Ceribell, Inc. (0001861107) (Subject)

    10/22/24 4:20:26 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Financials

    Live finance-specific insights

    View All

    Ceribell Reports Third Quarter 2025 Financial Results

    SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 Ended the quarter with 615 total active accounts Appointed Erica Rogers to the Board of Directors "We are encouraged by our third quarter performance, which re

    11/4/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025

    SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 93946

    10/21/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Reports Second Quarter 2025 Financial Results

    SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter of 2025Ended the quarter with 584 total active accounts  "We are pleased with our second quarter results, which reflect our successful commercial execution as we accelerate adopt

    8/5/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care